Practical experience of administering subcutaneous rituximab

Royal College of Nursing

Educator: Royal College of Nursing
Course Duration: 60 minutes

- +


Treatment regimens involving the monoclonal anti-CD20 antibody rituximab are the standard of care for patients with CD20-positive non-Hodgkin lymphoma (NHL). It has conventionally been given by intravenous (IV) infusion, which requires intermittent patient monitoring during administration. A subcutaneous (SC) formulation is also available for the treatment of NHL, which takes less time to administer and could simplify treatment. With the newer formulation available, there is an ongoing need for education and understanding from the patient’s and the healthcare professional’s perspective. The authors review their personal experience of rituximab IV and SC formulations together with data on their safety, and provide an overview of the use of SC formulation in daily nursing practice.

There are no reviews yet.

Be the first to review “Practical experience of administering subcutaneous rituximab”

Your email address will not be published.